



2ND WORLD CONGRESS

Devising Improved Methods for Identification
and Treatment of Infectious Diseases

Hyatt Regency Hotel
Boston, Massachusetts
October 28-30, 2007

PREMIER SPONSOR



Schering-Plough

PARTNER SPONSORS



SUPPORTING ORGANIZATIONS



PUBLISHING SPONSORS



Clinical Infectious Diseases

Mary Ann Liebert, Inc./Informa

Program

SYMPOSIUM & ROUNDTABLE: SUNDAY, OCTOBER 28TH (AFTERNOON)

Future Strategies in Drug Development and Prescribing

Co-Chairs: Ian Gould, MB; Christopher Spivey, MCom

Co-sponsored by the International Society for Chemotherapy (ISC) and the Alliance for the Prudent Use of Antibiotics (APUA)

- 2:00-2:30 Steven J. Projan, PhD, Biological Technologies, Wyeth Research: *“How can we control antibiotic resistance when we don’t understand it?”*
- 2:30-3:00 Dominique L. Monnet, PharmD, PhD, Antimicrobial Resistance and Healthcare-Associated Infections, Scientific Advice Unit, European Centre for Disease Prevention and Control: *“Encouraging development of new antibacterials while preserving the old”*
- 3:00-3:30 Robert C. Moellering, MD, Beth Israel Deaconess Medical Center, Harvard Medical School: *“New concepts of anti-infective therapy”*
- 3:30-3:45 **Break**
- 3:45-4:15 Ursula Theuretzbacher, PhD, Center for Anti-Infective Agents: *“Antimicrobials in the future”*
- 4:15-4:45 Margaret Riley, PhD, Director, Massachusetts Natural History Collections, Department of Biology, University of Massachusetts, Amherst: *“Applying ecological and evolutionary theory in the design of novel antimicrobials”*
- 4:45-5:15 **Roundtable Discussion**

MONDAY, OCTOBER 29TH (MORNING) PLENARY SESSION

Drug Policy and Economic Burden

Session Chair: Stuart B. Levy, MD

- 8:30-9:00 Susan Foster, PhD, Director of Public Policy and Education, Alliance for the Prudent Use of Antibiotics; Professor of International Health, Boston University School of Public Health: *“The economic burden of antibiotic resistance in the United States”*
- 9:00-9:30 Melvin P. Weinstein, MD, Professor of Medicine and Pathology, Chief, Division of Allergy, Immunology & Infectious Disease, Robert Wood Johnson Medical School: *“Establishing breakpoints for antimicrobial susceptibility testing: Methods and controversies”*
- 9:30-10:00 Eddie Power, PhD, Head of Anti-Infectives/Virology, Global Medical Affairs, Schering-Plough: *“Impact of antibiotic restrictions: The pharmaceutical perspective”*
- 10:00-10:15 **Break**
- 10:15-10:45 Solomon Nwaka, PhD, Scientist, Manager, Genomics and Discovery Research, Special Programme for Research in Tropical Diseases, World Health Organization: *“Identifying drug targets and research priorities”*
- 10:45-11:15 Sheila Smith, MA, Economist, National Health Statistics Group of the Centers for Medicare and Medicaid Services: *“Health system in flux; Looking ahead to the coming decade”*
- 11:15-11:45 Ramanan Laxminarayan, PhD, MPH, Senior Fellow, Resources for the Future; Visiting Scholar, Princeton University, : *“Extending the Cure”*
- 11:45-12:15 **Panel Discussion**
- 12:15-1:00 **Lunch**

MONDAY, OCTOBER 29TH (AFTERNOON) TWO SIMULTANEOUS TRACKS

Diagnostics

Session Chair: Helen H. Lee, PhD

- 1:00-1:30 Helen H. Lee, PhD, Associate Professor of Medical Biotechnology and Head of Diagnostics Developmental Unit, University of Cambridge, UK: *“Developing diagnostics for the real world”*
- 1:30-2:00 Huimin Kong, PhD, CEO, BioHelix Corporation: *“Disposable molecular diagnostics tests for hospital acquired infection”*
- 2:00-2:30 **Break**
- 2:30-2:45 David Gorenstein, PhD, Professor, Charles Marc Pomerat Distinguished Professor of Biological Sciences, Associate Dean of Research, University of Texas Medical Branch: *“Thioaptamers for diagnostics and broad-spectrum immunomodulation in infectious diseases”*
- 2:45-3:15 Ralph Timperi, MPH, Senior Advisor, Laboratory Practice and Management, Director Global Health Programs, Association of American Public Health Laboratories: *“Improving access to diagnostic testing in developing countries: Strategic considerations”*
- 3:15-3:45 **Panel Discussion**

Exhibitors:

With around 300 expected attendees this event is a wonderful opportunity to showcase your company’s new products and services. The 2nd World Congress Reception, conference sessions, and workgroup meetings will be located in the Hyatt Regency Hotel in Boston. APUA is able to offer 30 exhibit spaces at 100 square feet. With the exception of sponsors, exhibit spaces will be sold as orders are received and until they are sold out.



MONDAY, OCTOBER 29TH (AFTERNOON) TWO SIMULTANEOUS TRACKS

Infection Control

Session Chair: Ian Gould, PhD

- 1:00-1:30 Roberta Carey, PhD, Branch Chief of Epidemiology, CDC: “Multi-drug resistant organisms: How do we define them, how do we stop them?”
- 1:30-2:00 Janet Hindler, MCLS, MT(ASCP), UCLA Medical Center: “Educating clinical and public health laboratorians to deal with antimicrobial resistance challenges”
- 2:00-2:30 **Break**
- 2:30-2:45 Stephen M. Brecher, PhD, Director of Microbiology, VA Boston Healthcare System: “Addressing the challenge of C. difficile”
- 2:45-3:15 Ian Gould, MB, FRCPE, Consultant Microbiologist, Aberdeen Royal Infirmary, UK: “Antibiotic policies to control MRSA– Why not?”
- 3:15-3:45 **Panel Discussion**

TUESDAY, OCTOBER 30TH (MORNING) TWO SIMULTANEOUS TRACKS

Biodefense

Session Chair: Sally Hojvat, PhD

- 9:00-9:30 Jerome Donlon MD, PhD, Chief Scientific Advisor, Biomedical Advanced Research and Development Authority: “Public health emergency countermeasures”
- 9:30-10:00 Sally Hojvat, PhD, Director, Division of Microbiology Devices, Office of *In-vitro* Diagnostic Device Evaluation and Safety, CDRH, FDA: “Regulating diagnostic devices for emerging pathogens and biothreat agents”
- 10:00-10:15 **Break**
- 10:15-10:45 Jean D. Reed, MS, Special Assistant to the Secretary of Defense for Chemical and Biological Defense and Chemical Demilitarization Programs: “Developing capabilities in support of national strategies”
- 10:45-11:15 Patrick W. Flavin, Chief Legal Counsel, Advanced Life Sciences: “Leveraging a commercial indication to enter the biodefense market”
- 11:15-11:45 **Panel Discussion**

Immunomodulation

Session Chair: Arturo Casadevall, MD, PhD

- 9:00-9:30 Arturo Casadevall, MD, PhD, Leo and Julia Forchheimer Professor of Microbiology and Immunology, Professor, Department of Medicine (Infectious Disease), Albert Einstein College of Medicine: “Understanding the pathogenesis of infectious diseases: The damage-response framework”
- 9:30-10:00 John Mathison, PhD, Department of Immunology, The Scripps Research Institute: “Systems biology, innate immunity and infectious disease”
- 10:00-10:15 **Break**
- 10:15-10:45 Mary O’Riordan, PhD, Assistant Professor, Department of Microbiology and Immunology, University of Michigan Medical School: “Keeping bugs in their place: The role of compartmentalization in host-pathogen interactions”
- 10:45-11:15 Christine A. Biron, PhD, Brintzenhoff Professor of Medical Sciences, Department of Molecular Microbiology & Immunology, Brown University: “Modulating immune cell responsiveness to stimulatory pathways”
- 11:15-11:45 **Panel Discussion**
- 11:45-12:45 **Lunch**

TUESDAY, OCTOBER 30TH (AFTERNOON) PLENARY SESSION

Drug Innovation and Development

Session Chair: Jon Clardy, PhD

- 12:45-1:15 Thomas Evans, MD, Global Head of Infectious Disease, Novartis Institutes for Biomedical Research: “Collaboration and innovation in drug development”
- 1:15-1:45 Stefan Willemsen, LL.M, Head of Roche Applied Science Partnering, Roche Diagnostics, Switzerland: “Role of partnering in life science industry”
- 1:45-2:00 **Break**
- 2:00-2:30 Jon Clardy, PhD, Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School: “Genome sequencing, cryptic pathways and ecology: Antibiotic drug discovery at HMS and the Broad Institute”
- 2:30-3:00 Robert E. Yocher, RAC, MHSc, Vice President of Regulatory Affairs and Corporate Quality Compliance, Genzyme Corporation: “Co-development of diagnostics and drugs”
- 3:00-3:30 Patrick S. Doyle, PhD, Doherty Associate Professor of Chemical Engineering, Massachusetts Institute of Technology: “Multifunctional encoded particles for high-throughput biomolecule analysis”

End of Conference



Registration Form

Registration Fees:

Early Registration (Registration must be received by August 24, 2007):

- Student/Postdoc (\$159) Government/Academic (\$299) Commercial (\$499)

Advance Registration (Registration must be received by September 7, 2007):

- Student/Postdoc (\$199) Government/Academic (\$399) Commercial (\$599)

On-site Registration:

- Student/Postdoc (\$299) Government/Academic (\$499) Commercial (\$699)

Please check if you are a congress exhibitor and/or speaker: Exhibitor Speaker

Please check if you are an APUA member: APUA Member Non-member

Please indicate if you would like to present a poster: Poster

First name: _____ **Last name:** _____

Degree: _____ **Position:** _____

Organization: _____ **Department:** _____

Address: _____

City: _____ **State:** _____ **Zip:** _____

Country: _____ **Email:** _____

Phone: _____ **Fax:** _____

Please indicate expected sessions of attendance:

- Drug Policy and Legislation Drug Discovery & Development Economic Burden
 Diagnostics Biodefense/ Infection Control Immunomodulation

Please indicate involvement in past/present APUA programs:

- ROAR FAAIR GAARD Home hygiene
 Economic burden State of the State International chapters

Please indicate how you learned of the World Congress:

- APUA website Journal advertisement ICAAC related email
 Colleague APUA staff APUA booth at ICAAC Other

Payment Options:

- Check payable to APUA Mastercard Visa

Credit card number: _____ **Exp. Date:** _____

Total payment amount (Please circle amount):

- Student/Postdoc (\$159 if registered by 8/10/07) Government/Academic (\$299 if registered by 8/10/07) Commercial (\$499 if registered by 8/10/07)

Mail or fax this completed form to:

APUA World Congress Registration, 75 Kneeland Street, Boston, MA 02111, USA
 Phone: 617.636.0966 ♦ Fax: 617.636.3999 ♦ www.apua.org